The clonal evolution of tumor cell populations, Science, vol.194, pp.23-28, 1976. ,
Genetic instability and darwinian selection in tumours, Trends Cell Biol, vol.9, pp.57-60, 1999. ,
DOI : 10.1016/s0168-9525(99)01874-0
The multistep nature of cancer, Trends Genet, vol.9, pp.138-141, 1993. ,
Clonal evolution in cancer, Nature, vol.481, pp.306-313, 2012. ,
DOI : 10.1038/nature10762
URL : http://europepmc.org/articles/pmc3367003?pdf=render
Cancer: Evolution within a lifetime, Annu. Rev. Genet, vol.48, pp.215-236, 2014. ,
DOI : 10.1146/annurev-genet-120213-092314
Boveri at 100: Cancer evolution, from preneoplasia to malignancy, J. Pathol, vol.234, pp.146-151, 2014. ,
DOI : 10.1002/path.4408
Evolution of Premalignant Disease. Cold Spring Harb. Perspect, vol.7, 2017. ,
DOI : 10.1101/cshperspect.a026542
URL : http://perspectivesinmedicine.cshlp.org/content/7/12/a026542.full.pdf
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal, vol.26, pp.17-24, 2017. ,
DOI : 10.1016/j.ebiom.2017.11.024
URL : https://doi.org/10.1016/j.ebiom.2017.11.024
Accelerated and blastic phase of chronic myeloid leukemia, Curr. Treat. Options Oncol, vol.1, pp.51-62, 2000. ,
DOI : 10.1007/s11864-000-0015-z
Evolution of secondary hematologic disorders: preMDS->MDS->sAML, Cancer Treat. Res, vol.108, pp.185-230, 2001. ,
DOI : 10.1007/978-1-4615-1463-3_11
Chronic myeloid leukaemia as a model of disease evolution in human cancer, Nat Rev Cancer, vol.7, pp.441-453, 2007. ,
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias, Cancer Res, vol.70, pp.447-452, 2010. ,
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, pp.2220-2228, 2014. ,
Targeted sequencing identifies patients with pre-clinical MDS at high risk of disease progression, Blood, vol.126, pp.2362-2365, 2015. ,
Time-dependent changes in mortality and transformation risk in MDS, Blood, vol.128, pp.902-910, 2016. ,
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals, Blood, vol.86, pp.3118-3122, 1995. ,
JAK2 (V617F) mutation in healthy individuals, Br. J. Haematol, vol.136, pp.678-679, 2007. ,
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis, Nat. Genet, vol.44, pp.1179-1181, 2012. ,
Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med, vol.371, pp.2488-2498, 2014. ,
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N. Engl. J. Med, vol.371, pp.2477-2487, 2014. ,
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, pp.9-16, 2015. ,
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions, Oncotarget, vol.8, pp.73483-73500, 2017. ,
, Int. J. Mol. Sci, vol.20, p.789, 2019.
Pre-leukemic evolution of hematopoietic stem cells: The importance of early mutations in leukemogenesis, Leukemia, vol.28, pp.2276-2282, 2014. ,
Aging, clonal hematopoiesis and preleukemia: Not just bad luck?, Int. J. Hematol, vol.102, pp.513-522, 2015. ,
Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia, Exp. Hematol, vol.43, pp.989-992, 2015. ,
The shadowlands of MDS: Idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP), Hematology Am. Soc. Hematol. Educ. Program, pp.299-307, 2015. ,
The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia, Nat. Rev. Cancer, vol.17, pp.5-19, 2017. ,
, Diagnostic Criteria, Separation from MDS and Clinical Implications, vol.1, pp.1-9, 2018.
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease, N. Engl. J. Med, vol.377, pp.111-121, 2017. ,
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes, Best Pract. Res. Clin. Haematol, vol.26, pp.355-364, 2013. ,
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, vol.28, pp.241-247, 2014. ,
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact, Br. J. Haematol, vol.164, pp.822-833, 2014. ,
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations, Haematologica, vol.100, pp.125-127, 2015. ,
Dynamics of clonal evolution in myelodysplastic syndromes, Nat. Genet, vol.49, pp.204-212, 2017. ,
, Consequences of mutant TET2 on clonality and subclonal hierarchy, vol.32, pp.1751-1761, 2018.
Landscape of TET2 mutations in acute myeloid leukemia, Leukemia, vol.26, pp.934-942, 2012. ,
Subtype-specific patterns of molecular mutations in acute myeloid leukemia, vol.31, pp.11-17, 2017. ,
Comprehensive mutational profiling in advanced systemic mastocytosis, Blood, vol.122, pp.2460-2466, 2013. ,
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event, Leukemia, vol.29, pp.1115-1122, 2015. ,
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML, Blood, vol.127, pp.893-897, 2016. ,
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma, J. Clin. Oncol, vol.35, pp.1598-1605, 2017. ,
, Int. J. Mol. Sci, vol.20, p.789, 2019.
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: A case-control study, Lancet Oncol, vol.18, pp.100-111, 2017. ,
Molecular Minimal Residual Disease in Acute Myeloid Leukemia, N. Engl. J. Med, vol.378, pp.1189-1199, 2018. ,
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity, Nat. Immunol, vol.5, pp.738-743, 2004. ,
Targeting of leukemia-initiating cells to develop curative drug therapies: Straightforward but nontrivial concept. Curr. Cancer Drug Targets, vol.11, pp.56-71, 2011. ,
Cancer stem cell definitions and terminology: The devil is in the details, Nat. Rev. Cancer, vol.12, pp.767-775, 2012. ,
Concise review: Preleukemic stem cells: Molecular biology and clinical implications of the precursors to leukemia stem cells, Stem Cells Transl. Med, vol.2, pp.143-150, 2013. ,
Heterogeneity of neoplastic stem cells: Theoretical, functional, and clinical implications, Cancer Res, vol.73, pp.1037-1045, 2013. ,
Clonal architecture of secondary acute myeloid leukemia, N. Engl. J. Med, vol.366, pp.1090-1098, 2012. ,
The genetic basis of myelodysplasia and its clinical relevance, Blood, vol.122, pp.4021-4034, 2013. ,
Clinical significance of genetic aberrations in secondary acute myeloid leukemia, Am. J. Hematol, vol.87, pp.1010-1016, 2012. ,
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms, Leukemia, vol.30, pp.2270-2273, 2016. ,
The evolving genomic landscape of myeloproliferative neoplasms, Hematology Am. Soc. Hematol. Educ. Program, pp.287-296, 2014. ,
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proc. Natl. Acad. Sci, vol.111, 2014. ,
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation, Leukemia, vol.23, pp.1426-1431, 2009. ,
Genomic determinants of chronic myelomonocytic leukemia, Leukemia, vol.31, pp.2815-2823, 2017. ,
Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome, Am. J. Hematol, vol.90, pp.411-416, 2015. ,
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia, Blood, vol.128, pp.1408-1417, 2016. ,
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia, Sci. Transl. Med ,
Genomic Classification and Prognosis in Acute Myeloid Leukemia, N. Engl. J. Med, vol.374, pp.2209-2221, 2016. ,
, Int. J. Mol. Sci, vol.20, p.789, 2019.
Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat. Med, vol.20, pp.1472-1478, 2014. ,
Clinical significance of somatic mutation in unexplained blood cytopenia, vol.129, pp.3371-3378, 2017. ,
Effect of mutation order on myeloproliferative neoplasms, N. Engl. J. Med, vol.372, pp.601-612, 2015. ,
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression, Leukemia, vol.24, pp.1139-1145, 2010. ,
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases, Leukemia, vol.25, pp.557-560, 2011. ,
CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia, Blood, vol.117, pp.198-206, 2011. ,
Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site, Leukemia, vol.31, pp.2388-2397, 2017. ,
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome, Gastroenterology, vol.130, pp.2031-2038, 2006. ,
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis, J. Thromb. Haemost, vol.5, pp.55-61, 2007. ,
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders, J. Thromb. Haemost, vol.5, pp.708-714, 2007. ,
Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation, Thromb. Res, vol.132, pp.99-104, 2013. ,
JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science, Leukemia, vol.22, pp.1813-1817, 2008. ,
Somatic mutations of calreticulin in myeloproliferative neoplasms, N. Engl. J. Med, vol.369, pp.2379-2390, 2013. ,
Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms, Semin Hematol, vol.55, pp.215-222, 2018. ,
Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera, Br. J. Haematol, vol.175, pp.419-426, 2016. ,
Álvarez-Larrán, A. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up, Ann. Hematol, vol.97, pp.443-451, 2018. ,
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia, Haematologica, vol.100, 2015. ,
FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up, Leukemia, vol.12, pp.887-892, 1998. ,
Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes, vol.8, p.299, 2008. ,
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant, Clin. Cancer Res, vol.16, pp.2246-2256, 2010. ,
Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation, Eur. J. Haematol, vol.96, pp.65-71, 2016. ,
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features, Oncotarget, vol.7, pp.57021-57035, 2016. ,
Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis, Hematology, vol.21, pp.454-461, 2016. ,
ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS, Blood Cancer J, vol.7, p.633, 2017. ,
Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia, Ann. Lab. Med, vol.38, pp.495-502, 2018. ,
Qin Dong, X.; et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia, Am. J. Hematol, vol.88, pp.56-59, 2013. ,
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS, Am. J. Hematol, vol.89, pp.499-504, 2014. ,
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia, Curr. Opin. Oncol, vol.20, pp.711-718, 2008. ,
Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications, J. Clin. Oncol, vol.29, pp.475-486, 2011. ,
DOI : 10.1200/jco.2010.30.2554
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways, J. Clin. Oncol, vol.35, pp.934-946, 2017. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, pp.2391-2405, 2016. ,
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter, Blood Adv, vol.2, pp.3070-3080, 2018. ,
DOI : 10.1182/bloodadvances.2018020206
RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM), Semin. Hematol, vol.54, pp.75-80, 2017. ,
DOI : 10.1053/j.seminhematol.2017.04.006
, Mutations in Inherited and Sporadic Leukemia. Front. Cell. Dev. Biol, vol.5, 2017.
Familial CEBPA-mutated acute myeloid leukemia, Semin. Hematol, vol.54, pp.87-93, 2017. ,
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis, Cell. Biosci, vol.6, 2016. ,
, Int. J. Mol. Sci, vol.20, p.789, 2019.
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis, J. Allergy Clin. Immunol, vol.131, pp.605-607, 2013. ,
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms, Blood, vol.128, pp.1121-1128, 2016. ,
, Familial MPN Predisposition. Curr. Hematol. Malig. Rep, vol.12, pp.442-447, 2017.
Unique effects of KIT D816V in BaF3 cells: Induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens, J. Immunol, vol.180, pp.5466-5476, 2008. ,
Sexl, V. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia, Oncotarget, vol.3, pp.1669-1687, 2012. ,
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression, Leukemia, vol.27, pp.2187-2195, 2013. ,
Right on target: Eradicating leukemic stem cells, Trends Mol. Med, vol.13, pp.470-481, 2007. ,
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells, Blood Cells Mol. Dis, vol.55, pp.336-346, 2015. ,
Cancer stem cells in basic science and in translational oncology: Can we translate into clinical application?, J. Hematol. Oncol, vol.8, p.16, 2015. ,
Translation of the Philadelphia chromosome into therapy for CML, Blood, vol.112, pp.4808-4817, 2008. ,
Five years since the discovery of FIP1L1-PDGFRA: What we have learned about the fusion and other molecularly defined eosinophilias, Leukemia, vol.22, 1999. ,
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase, Leukemia, vol.27, pp.2254-2256, 2013. ,
Emerging treatments for classical myeloproliferative neoplasms, vol.129, pp.693-703, 2017. ,
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis, N. Engl. J. Med, vol.374, pp.2530-2541, 2016. ,
Midostaurin: A magic bullet that blocks mast cell expansion and activation, Ann. Oncol, vol.28, pp.2367-2376, 2017. ,